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Abstract
Sir Almroth Wright coordinated the first trial of a whole-cell pneumococcal vaccine in South Africa from 1911 to 1912. Wright started
a chain of events that delivered pneumococcal vaccines of increasing clinical and public-health value, as medicine advanced from a vague
understanding of the germ theory of disease to today’s rational vaccine design. Early whole-cell pneumococcal vaccines mimicked early
typhoid vaccines, as early pneumococcal antisera mimicked the first diphtheria antitoxins. Pneumococcal typing systems developed by
Franz Neufeld and others led to serotype-specific whole-cell vaccines. Pivotally, Alphonse Dochez and Oswald Avery isolated pneumo-
coccal capsular polysaccharides in 1916–17. Serial refinements permitted Colin MacLeod and Michael Heidelberger to conduct a 1944–
45 clinical trial of quadrivalent pneumococcal polysaccharide vaccine (PPV), demonstrating a high degree of efficacy in soldiers against
pneumococcal pneumonia. Two hexavalent PPVs were licensed in 1947, but were little used as clinicians preferred therapy with new
antibiotics, rather than pneumococcal disease prevention. Robert Austrian’s recognition of high pneumococcal case-fatality rates, even
with antibiotic therapy, led to additional trials in South Africa, the USA and Papua New Guinea, with 14-valent and 23-valent PPVs
licensed in 1977 and 1983 for adults and older children. Conjugation of polysaccharides to proteins led to several pneumococcal conju-
gate vaccines licensed since 2000, enabling immunization of infants and young children and resultant herd protection for all ages. Today,
emergence of disease caused by pneumococcal serotypes not included in various vaccine formulations fuels research into conserved
proteins or other means to maximize protection against more than 90 known pneumococcal serotypes.
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On 4 October 1911, British physician Sir Almroth E. Wright
(1861–1947) began a series of at least three studies testing
whole-cell heat-killed pneumococcal vaccine among several
thousand gold miners who had come from tropical areas to
the mine compounds in Johannesburg, in the Transvaal prov-
ince of South Africa [1–4]. Wright did not realize at the time
the remarkable serotype specificity of Streptococcus pneumo-
niae. He did realize the enormous burden of a sudden-onset
disease with a 35% case-fatality rate [4–6].
Nonetheless, Wright’s evaluation of that first pneumococ-
cal vaccine a century ago started a chain of events that has
delivered pneumococcal vaccines of increasing clinical and
public-health value [1–3]. The progress from vague under-
standing of the germ theory of disease in 1911 to today’s
rational vaccine design is remarkable. At this centennial of
the first human trial of pneumococcal vaccination, conducted
under Wright’s direction by G.D. Maynard [2,3], this paper
reviews the slow, but inexorable, progress from crude to
refined vaccines (and antisera) over the last 100 years.
The early years: isolation and serum
therapy
George M. Sternberg (1838–1915), a US Army physician, and
the renowned Louis J. Pasteur (1822–1895) independently
isolated S. pneumoniae by animal passage in New Orleans and
Paris, respectively, in 1880 [7–10]. During subsequent dec-
ades, this pathogen was the focus of considerable scientific
attention, as it was recognized to be a principal cause of
pneumonia, bacteraemia and meningitis [10,11]. This bacte-
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rium was assigned the name Diplococcus pneumoniae in 1920
and was revised to Streptococcus pneumoniae in 1974; infor-
mally, it has long been known as the pneumococcus [3,12].
Evaluation of pneumococcal vaccines in the early 1910s
was not the beginning of attempts toward immunological
therapy of pneumococcal disease. Albert Fra¨nkel (1864–
1938) was the first to demonstrate humoral immunity fol-
lowing pneumococcal infection of animals (rabbits) in 1886.
He noted that rabbits who recovered from pneumococcal
infection were immune to re-infection [13,14]. Georg Klem-
perer (1865–1946) and his brother Felix Klemperer (1866–
1932) showed in 1891 that serum from rabbits injected with
heat-killed pneumococci (or filtrates of broth cultures) con-
ferred immunity to re-infection with the same strain, but not
necessarily different strains [15]. On this basis, they are con-
sidered the discoverers of serum therapy.
By 1895, anti-pneumococcal serum appeared in the H.K.
Mulford catalogue (where it remained into the 1940s)
(Fig. 1) [16]. Early forms of this product would have been
justified on an empirical basis, by analogy to diphtheria anti-
toxin. Early studies of antiserum therapy of pneumococcal
infections came in the 1910s. Neufeld, Alphonse R. Dochez
(1882–1964) and Rufus I. Cole (1872–1966) contributed
information about such treatment for patients with pneumo-
nia [17–19]. In 1915, Oswald T. Avery (1877–1955) fraction-
ated serotype 1 antipneumococcal serum with ammonium
sulphate as a means of concentrating the product; others
developed other means of concentration [16,20].
Russell L. Cecil (1881–1965) and his colleagues reported
large series of patients treated with serotypes 1 and 2, or 1,
2 and 3 antiserum at Bellevue Hospital in New York City in
the late 1920s and 1930s [20–23]. The death rate for recipi-
ents of serotype 1 antiserum was 13%, compared with his-
torical controls with serotype 1 disease who did not receive
the serum (22%). Similarly, for serotype 2 the case-fatality
rate was 28% compared with 40%. For serotype 3 the case-
fatality rate was unchanged (40% in historical controls and in
serum-treated patients).
From empirical vaccines to specific ones
Before Wright administered two doses of whole cell, killed
pneumococcal vaccine to the miners in his randomized clini-
cal trial, early vaccine manufacturers had already begun mar-
keting whole-cell pneumococcal vaccines. The first specific
record to our knowledge is the pneumococcal vaccine
(‘Pneumo-Bacterin’) licensed in the USA in 1909, with manu-
facturers such as H.K. Mulford Co., Eli Lilly & Company
(Figs 2 and 3), and Parke, Davis & Co.
These early whole-cell heat-treated products empirically
mimicked whole-cell typhoid, cholera and plague vaccines that
had already achieved some degree of clinical success. Distribu-
tion continued into the 1930s; their product licences remained
bureaucratically (if not commercially) active until c. 1960.
These products took form in a variety of injectables and tab-
lets, combining killed pneumococci with other bacterial vac-
cines such as Staphylococcus aureus, Neisseria (Moraxella)
catarrhalis, the bacillus of Friedlander (Klebsiella), Bacillus (Hae-
mophilus) influenzae, and others. Some formulations used a
mineral-oil or cottonseed-oil base (lipovaccines), rather than
an aqueous base, to prevent autolysis, increasing the bacterial
dose per volume, and to slow down absorption [24].
In Wright’s first study between October 1911 and April
1912, 5963 vaccinees were compared with 5671 controls.
The whole-cell vaccine doses (developed from circulating
strains, but without regard to serotype specificity) ranged
from 300 million to 600 million organisms given subcutane-
ously in two doses 8–10 days apart [1]. The results among
the vaccines and controls were imprecisely recorded, so a
second study in more than 8000 miners began in August
1912. The vaccine in this second study, also produced with-
out regard to capsular type, ranged from 40 million to >2.5
billion organisms per dose 7–12 days apart. This second vac-
cination study offered protection (19.5 attacks of pneumonia
per 1000 vaccinees compared with 26.4 per 1000 controls
over 6 months), but protection was only evident during the
first 2 months. Wright also noted that respiratory diseases
other than pneumonia were reduced in vaccinees during the
first 2 months, but the case-fatality rate of pneumonia was
not reduced. In the third trial, started in late 1912, a dose of
500 million organisms apparently reduced pneumonia inci-
dence by 25–50% and the death rate by 40–50% [3]. Pneu-
monia was also reduced in a subsequent trial of diamond
miners at the Premier diamond mine in 1912 [1].
FIG. 1. Antipneumococcic serum packaging. Source: H. K. Mulford
Company catalogue, Philadelphia, PA, USA, May 1914:286.
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As Wright was conducting his trials, realization of the
serotype-specificity of the pneumococcus was rising. In 1909,
at the Robert Koch Institute for Infectious Diseases in Berlin,
Franz Neufeld (1861–1945) and Ludwig Ha¨ndel (1869–1939)
developed a method to distinguish serotypes of pneumococci
[10,17,24,25]. They took advantage of the quellung (‘swelling’)
reaction, in which antibodies bind specifically to certain sub-
sets of pneumococcal capsules, such that they are more eas-
ily viewed microscopically. The serum specificity of this
reaction leads to the term serotype. They also developed a
mouse protection test to measure the degree of immunity
[24]. Dochez, at the Rockefeller Institute for Medical
Research in New York City, extended Neufeld’s groups to
include three serotypes and a fourth heterogeneous group
yet to be categorized [10,26,27]. The contemporary ‘Danish’
classification system was developed by Edna Lund and col-
leagues at the Statens Seruminstitut, Copenhagen, in the
1950s [12].
Independently, Wright’s South African prote´ge´ Sir F. Spen-
cer Lister (1876–1939) developed a distinct typing system
based on phagocytosis and specific agglutination at the South
African Institute for Medical Research in Johannesburg. He
found additional virulent strains in his setting that were not
found in Europe or North America [3–5,24,28,29]. Lister
used his typing system in 1914 to develop the first serotype-
specific whole-cell pneumococcal vaccines, containing his ser-
otypes A, B and C [30]. Serotypes B and C corresponded to
serotypes 2 and 1, respectively (although Roman numerals
were used in the early twentieth century). Serotype A was
not known in North America at that time, but is now known
to be serotype 5 [24].
Lister demonstrated that there were predominant sero-
types of pneumococci and advocated a new approach to vac-
cine trials, arguing (probably correctly) that immunization of
half of the workers at a mine may protect those unvacci-
nated through interruption in transmission [30]. Eventually,
Lister advocated immunizing all workers at a mine and com-
paring records of pneumonia to those pre-vaccination. In his
Crown Mine ‘experiment,’ c. 11 000 black South African min-
ers were vaccinated with three doses at 7-day intervals; 82
FIG. 2. Pneumococcus vaccine, prophylactic and therapeutic (pneu-
mococcus bacterin) packaging, ‘1000 million killed pneumococci in
each c.c.,’ likely Types I, II and III. Source: Hand Book of Pharmacy
and Therapeutics. Eli Lilly and Company, Indianapolis, IN, USA,
1919:208.
FIG. 3. Pneumococcus antigen packaging, types I, II, III and IV, 20 bil-
lion partially autolysed pneumococci per 1 c.c. Source: Hand Book
of Pharmacy and Therapeutics. Eli Lilly and Company, Indianapolis,
IN, USA, 1925:222.
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cases of lobar pneumonia subsequently occurred, but none
caused by pneumococcal groups A, B or C [24,29]. These
studies were conducted at the Crown, Premier and De
Beer’s Consolidated Diamond Mines, as well as the Rand
Gold Mines.
Lister reported in 1917 on pneumonia incidence rates
among newly arrived miners immunized at three mines, com-
paring them to rates before immunization. Critically, his
studies did not document the serotype distribution of pneu-
mococcal isolates at each mine before immunization, but
used a mixture of strains in his vaccines based on isolates
generally collected over the period and representing perhaps
<1% of the pneumonia cases at the mines [3]. Medical staff
arranged for all miners to receive Lister’s eight-valent vaccine
from 1918, but by 1926 it appeared that effectiveness had
waned, attributed to inadequate coverage (<40%) of circulat-
ing pneumococcal serotypes and other pneumonia-causing
bacterial species [31]. Notably, in a serotype analysis of
pneumococcal pneumonia isolates from 1930 to 1934, the
incidence of pneumococcal pneumonia cases caused by vac-
cine serotypes 1, 2, 5 and 7 was halved among vaccinees
compared with those not vaccinated, whereas the rate of
serotype 3 cases (also in the vaccine) was three-fold higher
in vaccinees than in controls [3,31].
As the pneumonia and other severe pulmonary manifesta-
tions of the 1918–19 influenza pandemic arose, amid the cli-
max of World War I, research teams offered their various
heat-inactivated, whole-cell bacterial vaccines (labelled in var-
ious ways as ‘influenza vaccines’, and usually including S. pneu-
moniae components [24,32]. One commentator decried the
‘mushroom’ vaccines that rapidly sprouted up to respond to
that emergency, noting that many of them were ‘shotgun’
vaccines containing many bacterial components, but of
unclear clinical value [24]. These vaccine makers were wrong
about a bacterial aetiology for influenza viral infection; how-
ever, they were inadvertently on the right track in terms of
the secondary bacterial pneumonias induced by influenza
viral infection [33].
Early tests of pneumococcal serotypes 1, 2 and 3 vaccine
occurred at Camp Upton, New York, and Camp Wheeler,
Georgia, in 1918–19, with substantial reductions in serotype-
specific pneumonia incidence among the vaccinees compared
with those unvaccinated [21,34,35].
To apply modern epidemiological methods to the 1918–
19 data, Chien and colleagues reanalysed studies of bacterial
vaccine efficacy from that era and calculated vaccine efficacy
of 34% in preventing pneumonia and 42% in reducing case-
fatality rates among six civilian studies of patients with influ-
enza, using random-effects models [33]. Based on fixed-effect
models in their 2010 analysis, the pooled efficacy from three
military studies was 59% for pneumonia and 70% for case-
fatality. Military studies showed less heterogeneity and may
provide more accurate results than civilian studies, given the
various forms of selection and information biases. The
authors concluded that the systematic biases in these studies
do not exclude the possibility that whole-cell inactivated
pneumococcal vaccines conferred cross-protection to multi-
ple pneumococcal serotypes or that bacterial vaccines played
a role in preventing influenza-associated pneumonia.
Advances using the pneumococcal capsule
In 1916–17, Dochez and Avery isolated what we know today
as capsular polysaccharides, but which they called ‘soluble
specific substances of pneumococcus’ or SSS [10,19,36,37].
Between 1923 and 1929, Avery and Michael Heidelberger
(1888–1991) at the Rockefeller Institute conducted a series
of studies establishing capsular antigens as the basis of the
serotypes of pneumococcal bacteria [37–39]. Rene´ J. Dubos
(1901–1982) and Avery established the critical role of the
pneumococcal capsule as a virulence factor in 1931
[10,40,41].
In 1927, Oscar Schiemann and Wolfgang Casper discov-
ered the immunogenicity of pneumococcal capsular polysac-
charides working at the Koch Institute [19,42,43]. In 1930,
Thomas Francis Jr (1900–1969) and William S. Tillett (1892–
1974), working at Harvard University and the Rockefeller
Institute, injected pure pneumococcal polysaccharides as a
form of skin test in people recovering from pneumococcal
pneumonia. Their goal was to identify whether serotype-spe-
cific pneumococcal antibodies evoked by polysaccharides
were present. Indeed, they found that antibodies developed
not only to the polysaccharide serotype causing infection but
also, in a group repeatedly tested, to the serotypes previ-
ously injected [44–46]. Maxwell Finland (1902–1987) used
these findings to conduct studies assessing the relation of
polysaccharide dose to immunological responsiveness
[11,47].
In 1929, Avery covalently coupled (i.e. conjugated) pneu-
mococcal polysaccharides to proteins to improve immunoge-
nicity. The proteins evaluated were horse globulin and egg
albumin, and the polysaccharides were presumably serotypes
1 and 2 [48]. It would take several decades for this develop-
ment to achieve practical clinical value.
Working at Harvard Medical School and Johns Hopkins
University in the 1920s and 1930s, Lloyd D. Felton (1885–
1956) showed that pure pneumococcal polysaccharides
induced antibody in humans [46,49,50]. He developed biva-
lent vaccines against serotypes 1 and 2 that were tested in
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field trials during the 1930s among 120 000 men at Civilian
Conservation Corps camps [5,19,51–53]. These trials were
inconclusive, partly because bacteriological studies after vac-
cination were incomplete and partly because of the open-air
character of the camps.
An epidemic of lobar pneumonia at the main adult psychi-
atric hospital in Worcester, Massachusetts, provided an
opportunity to assess serotype 1 pneumococcal infections in
1937 [54]. After immunization of patients and staff with a
serotype 1 pneumococcal polysaccharide antigen (‘Felton
antigen’) produced by Lederle Laboratories (Pearl River,
New York), the outbreak was abruptly interrupted. Curi-
ously, the outbreak next arose within 2 weeks at an annex
facility 5 km (3 miles) away. Again, the antigen was widely
administered and the outbreak was stopped.
In 1941, Felton et al. directly compared serotype-specific
whole-cell pneumococcal vaccines and polysaccharide pneu-
mococcal vaccines in humans [55]. They tested 79 adults with
bivalent whole-cell serotypes 1 and 2 pneumococcal vaccine
with a dose of 225 million organisms of each serotype, fol-
lowed 14 days later with 450 million organisms of each sero-
type. They contrasted these results with two cohorts of 92
and 1099 adults who received 400 lg serotype-1 polysaccha-
ride and 200 lg serotype-2 polysaccharide. The authors found
no significant differences with respect to protective titres
induced, individual variation in response, or the percentage of
recipients without detectable serum antibody [55].
Wartime urgencies revisited
From 1942 to 1945, Heidelberger and Colin M. MacLeod
(1909–1972) took advantage of the preceding developments
in polysaccharide technology to develop and test a pneumo-
coccal polysaccharide vaccine at the US Army Air Force
Technical School, Sioux Falls, South Dakota [53,56,57]. In
this institutional setting with a high incidence rate of pneu-
mococcal infections, they tested capsular polysaccharides
against pneumococcal serotypes 1, 2, 5 and 7.
In the study over 7 months of the winter of 1944–1945,
four cases of vaccine-type pneumococcal pneumonia devel-
oped among 8586 vaccine recipients, in contrast to 26 cases
among 8449 controls injected with saline as placebo. All four
cases among vaccinees developed within 2 weeks of vaccina-
tion. Cases of non-vaccine-type pneumococcal pneumonia
postvaccination occurred at comparable rates in each group.
Interestingly, the pneumococcal carriage rate in vaccine
recipients was significantly lower than in the control group
in this study, similar to findings from South Africa in the
1970s [56–59].
Paul Kaufman extended this study by assessing older sub-
jects of both sexes at a residential institution in New York
City [60]. Among more than 5000 vaccinees, the research
team calculated a 90% reduction in pneumococcal pneumonia
and bacteraemia due to vaccine serotypes 1, 2 and 3. It
would not be until the 1970s that the inadequate antibody
response to pneumococcal polysaccharides of most children
younger than 2 years of age would be recognized [11,19,61].
In 1947, E.R. Squibb & Sons obtained a licence in the USA
to distribute two forms of hexavalent pneumococcal polysac-
charide vaccine, based on clinical data to that point
[46,53,56,60,62]. Squibb’s adult formulation contained poly-
saccharides for serotypes 1, 2, 3, 5, 7 and 8. The epidemiol-
ogy of serotype distribution led to different choices for the
paediatric vaccine formulation: serotypes 1, 4, 6, 14, 18 and
19. Squibb’s vaccines were not widely adopted, because post-
war clinicians preferred to treat pneumonias with newly
introduced antibiotics, like penicillin, chlortetracycline and
chloramphenicol [6,10,11,53]. Prevention of infection through
vaccination was disregarded. Production of the two hexava-
lent vaccines ceased in 1951 and Squibb voluntarily withdrew
their licences in 1954, because of lack of acceptance and
inadequate sales.
Randomized clinical trials of 1970s
Little additional research or development on pneumococcal
polysaccharide vaccines (PPVs) was conducted by pharma-
ceutical manufacturers until 1968, when Eli Lilly & Co. began
preparing vaccines under contract from the US National
Institutes of Health (NIH) [63]. In turn, this NIH effort was
motivated by a singular clinician-scientist named Robert
Austrian (1916–2007). Austrian could not accept the treat-
ment failures of a fast-incubating pathogen like S. pneumoniae
(17–30% mortality, despite antibiotic therapy, at Kings
County Hospital in Brooklyn) [6,11,19,64]. Austrian cata-
logued the frequency of inadequate therapy of pneumococcal
diseases, organized epidemiological surveys of serotype fre-
quency, and organized additional clinical trials of PPVs to
determine their clinical value. Austrian’s career was based at
the Bellevue Hospital in New York City, then the Rockefel-
ler Institute, and later at the University of Pennsylvania. He
attributed the under-recognition of pneumococcal disease
aetiology in part to insufficient attention to laboratory-based
diagnosis (including serotyping) [11].
Beginning in August 1972, Austrian coordinated clinical tri-
als of hexavalent and 12-valent pneumococcal vaccines in
c. 12 000 Witwatersrand gold miners in the Transvaal region
of South Africa (e.g. East Rand Preparatory Mine), harkening
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back to Wright’s work a century ago [4,11,63,65]. Briefly, a
hexavalent vaccine containing groups/types 1, 3, 4, 7, 8 and
12 and later a 13-valent formulation of groups/types 1, 2, 3,
4, 6, 7, 8, 9, 12, 14, 18, 19 and 25 (both produced by Eli
Lilly) were administered in a randomised fashion (50 lg each
polysaccharide serotype per 0.5-mL dose) to newly recruited
miners on their day of arrival at the mines in Johannesburg.
Volunteers were randomly divided into three groups, to
receive either PPV, a meningococcal serogroup A polysac-
charide vaccine (Merrell–National Laboratories), or a sterile
saline injection.
Meanwhile, Lilly was having difficulty developing its formu-
lation of PPV and chose in 1975 to invest its human and
other capital in other therapeutic areas [63]. Part of Lilly’s
calculus included the relative rarity of documented pneumo-
coccal disease and the difficulty of confirming its diagnosis.
This problem was mitigated by the self-funded pneumococcal
research programme that Merck Sharp and Dohme (MSD)
began in 1970, building on its expertise acquired in develop-
ing and producing a meningococcal polysaccharide vaccine
for the US Army [19,66]. The companies developed vaccine
formulations of various valencies, but only after testing each
individual polysaccharide for safety and immunogenicity.
In the early 1970s, MSD conducted clinical trials among
c. 4700 gold miners at the Kloof Gold Mine and Gold Fields
West near Johannesburg, led by Pieter Smit, demonstrating
safety and a 76% reduction in pneumococcal pneumonia
cases for the hexavalent vaccine and a 92% reduction in
cases for the 12-valent vaccine [59,63]. MSD’s findings were
comparable to those found for Lilly’s product used by Aus-
trian [65].
At the same time, the National Institute for Allergy and
Infectious Diseases contracted with clinical investigators in
universities and private practice to conduct US clinical trials
of pneumococcal vaccine. Austrian was principal investigator
for the studies at the Dorothea Dix Hospital in Raleigh and
at the Kaiser Permanente Medical Center in San Francisco
[11,19,65,67,68]. Important studies showing reductions in
morbidity and mortality in children and adults were con-
ducted in Papua New Guinea as well, coordinated by Ian
Riley and colleagues [69–72].
Meanwhile, increasing reliance on antibiotic therapy was
leading to antibiotic-resistant strains of pneumococci causing
pneumococcal diseases [6,10,11]. This situation offered a
better reception to a fledgling pneumococcal vaccine than
was the case in the late 1940s. The results of all these trials,
coupled with serotype surveillance from North America,
Europe and South Africa, led MSD to submit a licence appli-
cation for a 14-valent PPV that was approved in November
1977. In January 1978, the US Advisory Committee on
Immunization Practices (ACIP) recommended the vaccine for
people 2 years or older with certain chronic health condi-
tions that increased the risk of pneumococcal infection or as
an outbreak control measure in institutions [73]. In 1979,
Lederle Laboratories also introduced a 14-valent PPV. Table 1
summarizes various vaccine characteristics and introductions.
The basis for licensure for both products was based on
reductions in invasive pneumococcal disease and pneumococ-
cal pneumonia in the studies performed in the 1970s.
PPV14 was indicated for people 50 years and older, or
those 2 years and older with certain underlying health condi-
tions. Its 14 serotypes targeted 70–80% of invasive pneumo-
coccal disease (IPD) in the US [73–75].
Pneumococcal experts recognized the need for expanded
protection against a wider array of serotypes, so a broader
global survey of invasive pneumococcal isolates coordinated
by multiple national governments and the World Health
Organization led to a decision to recommend 23-valent vac-
cines. Thus PPV23 was introduced in 1983 by both Merck
and Lederle, with serotypes covering about 87% of bactere-
mic pneumococcal disease in the US [74–77]. PPV23 formu-
lations contain 25 mcg per polysaccharide antigen, rather
than the 50 mcg per antigen in PPV14 (Table 1). The transi-
tion was intended to better balance immunogenicity and
safety [75]. The ACIP recommendations published in May
1984 were the first to encourage routine vaccination of
healthy adults 65 years or older [77].
The manufacturing complexity for any vaccine with so
many individual components should not be underestimated.
Effectively 23 distinct vaccines within one formulation, PPV23
production involves 23 separate fermentations, isolation and
purification of their capsular polysaccharides, and then blend-
ing 23 polysaccharides into one liquid solution. Each vaccine
lot requires hundreds of assays for lot release, from master
cell bank through final product. These assays include tests
for identity, concentration, purity, potency/strength, and
safety. In the case of multivalent pneumococcal conjugate
vaccines (PCVs, discussed below), the conjugation and adju-
vant steps add more complexity.
From polysaccharides to conjugates
Pneumococcal polysaccharide vaccines are poorly immuno-
genic in children younger than 2 years of age, who are at
high risk of invasive pneumococcal disease. To improve the
immune response to the capsular polysaccharide in young
children, third-generation vaccines in which capsular polysac-
charides are conjugated to one of several different proteins
were developed and tested [78].
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Around 1980, John B. Robbins and Rachel Schneerson
picked up on Avery’s work [48], to develop polysaccharide–
protein conjugation technology further. Using capsular poly-
saccharides from Haemophilus influenzae type b (Hib) and
pneumococcal serotype 6A, they tested serum albumin, Limu-
lus haemocyanin, diphtheria toxin, cholera toxin and tetanus
toxoid as carrier proteins, in early studies at the Food and
Drug Administration laboratories [79–82]. Unlike other
researchers they did not need complete Freund’s adjuvant
or administration by intravenous or intraperitoneal routes to
enhance immunogenicity. Their success hinged on developing
methods to bind the polysaccharide units to the carrier pro-
teins.
The first protein-conjugated polysaccharide vaccines
achieved licensed status in the USA in 1987, in the form of
conjugated Hib vaccines. PCVs followed in 2000 (Table 1).
Routine use of PCV7 (which does not include serotype 19A)
was associated with increasing incidence of disease due to
serotype 19A [83,84], often referred to as emergence or
replacement disease. This phenomenon highlights the public-
health value of pneumococcal vaccines with broad serotype
coverage. Ten-valent and 13-valent PCVs are currently mar-
keted; Merck is developing a 15-valent PCV.
Routine vaccination of infants and young children has led
to a prompt and sustained reduction among vaccinees in
invasive pneumococcal disease involving corresponding
vaccine serotypes. Remarkably, the burden of invasive pneu-
mococcal disease among older children and adults who did
not receive PCV has also fallen markedly in the context of
routine paediatric vaccination programmes [83,84]. This
herd-protection effect is most likely the result of reduced
transmission of vaccine-type pneumococci in the community
as a result of decreased carriage.
Beyond the pivotal role of PCVs in protecting infants and
young children, while offering the potential for indirect pro-
tection of others, clinicians are now considering the relative
merits of PPVs and PCVs for adults. In 2012, the only avail-
able randomized controlled trial results for preventing pneu-
mococcal disease in adults describe the performance of PPVs
and evaluate clinical endpoints [85–89]. The recent licensure
of PCV13 for adults is based on non-inferiority of antibody
concentrations in relation to PPV23 serotypes in common.
PCV13 is the subject of a randomized controlled trial in the
Netherlands on adults that eventually will compare its clinical
performance to a saline placebo [90]. The two vaccine types
will need to be evaluated in the light of evolving serotype
distribution of pneumococcal diseases in both children and
adults.
Conclusions and future prospects for
pneumococcal vaccines
A century of development of pneumococcal vaccines in
humans has seen first whole-cell vaccines, then polysaccha-
ride vaccines with valencies ranging from 1 to 23, and finally
protein-conjugated polysaccharide vaccines with valencies
ranging from 5 to 15.
The future may include conserved pneumococcal protein
vaccines, currently in clinical trials [91]. Further, it may be
‘back to the future’ to return to whole-cell vaccines to pre-
vent replacement disease, as animal data suggest that whole-
cell non-encapsulated pneumococcal vaccine may protect
against a variety of serotypes [91].
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14-valent: 1, 2, 3, 4, 5, 6A, 7F, 8, 9N, 12F, 18C, 19F, 23F, 25F November 1977, USA
August 1979, USA
February 1981, France
SmithKline Beecham (Moniarix) 17-valent: 1, 2, 3, 4, 6A, 7F, 8, 9N, 11A, 12F, 14,
15F, 17F, 18C, 19F, 23F, 25
1980s, Europe
Merck Sharp & Dohme (MSD) (Pneumovax 23)
Lederle Laboratories (Pnu-Imune 23)
Institut Me´rieux (Pneumo 23)
Chengdu Institute of Biological Products
23-valent: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14,
15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F
July 1983, USA
July 1983, USA
1987, Europe
2005, China
Pneumococcal conjugate vaccines
Wyeth Laboratories (Prevnar or Prevenar) 7-valent: 4, 6B, 9V, 14, 18C, 19F, 23F February 2000 for infants, USA and Europe
GlaxoSmithKline (Synflorix) 10-valent: 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F March 2009 for infants: Europe
Wyeth Laboratories (Prevnar 13 or Prevenar 13) 13-valent: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F February 2010 for infants, late 2011 for
adults, Europe, Australia, USA
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Physicians of Philadelphia (and its HistoryofVaccines.org Pro-
ject) are greatly appreciated.
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